EBOS Group Limited

EBO

NZEBOE0001S6

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
35.17 ^NZD	-0.90%		+2.84%	-0.93%

Apr. 28	Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00	MT
Apr. 26	New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	MT

EBOS Group Ltd. Reaffirms Earnings Guidance for the Six Months Ending December 31, 2013

October 22, 2013 at 06:36 pm EDT

EBOS Group Ltd. reaffirmed its earnings guidance for the six months ending December 31, 2013. For the period, the company reported that it expects to meet its forecast net profit of NZD 48.7 million on revenue of NZD 3.17 billion.

Latest news about EBOS Group Limited

Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00	Apr. 28	MT
New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	Apr. 26	MT
Ebos Group Appoints New CFO	Apr. 25	MT
EBOS Group Limited Announces Chief Financial Officer Changes	Apr. 25	CI
Evans & Partners Starts Ebos Group at Positive, Price Target is NZ$40.94	Apr. 23	MT
Ebos Group Declares DRP Strike Price for Interim Dividend	Mar. 13	MT
Morgan Stanley Adjusts EBOS Group’s Price Target to AU$37 From AU$38, Keeps at Overweight	Mar. 05	MT
Morgan Stanley Adjusts EBOS’ Price Target to NZ$39.20 From NZ$41.05, Keeps at Overweight	Mar. 05	MT
EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 21	CI
EBOS Group Limited to Seek M&A	Feb. 20	CI
Transcript : EBOS Group Limited, H1 2024 Earnings Call, Feb 21, 2024	Feb. 20
EBOS Posts 7% Rise in Half Year FY24 Revenue, EPS Up 6.6%	Feb. 20	MT
Correction: --EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Billion; Underlying EPS of AU$0.795	Feb. 20	MT
EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Million; Underlying EPS of AU$0.795	Feb. 20	MT
EBOS Group Limited Announces Interim Dividend of the Year Ending June 30, 2024, Payable 22 March 2024	Feb. 20	CI
New Zealand shares post biggest weekly jump since Nov; Australia closed	Jan. 26	RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed	Jan. 25	RE
New Zealand Shares Rise on Tuesday on Upbeat Economic Data; EBOS Raises Ownership in Transmedic to 90%	Dec. 18	MT
EBOS Group Raises Transmedic Stake to 90% from 51%	Dec. 18	MT
EBOS Group Limited acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.	Dec. 18	CI
Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk	Dec. 13	CI
EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit	Dec. 04	CI
NZ's EBOS not to proceed with $2.44 billion Greencross acquisition	Nov. 21	RE
NZ's EBOS not to proceed with acquisition in animal care segment	Nov. 21	RE
EBOS Not to Proceed with Acquisition in Animal Care Segment	Nov. 21	CI

Chart EBOS Group Limited

Duration

Period

More charts

Company Profile

EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.

Sector

Pharmaceuticals

Calendar

2024-08-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for EBOS Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

35.17 NZD

Average target price

37.99 NZD

Spread / Average Target

+8.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
EBOS GROUP LIMITED	-0.93%	4.16B
MCKESSON CORPORATION	+21.82%	73.31B
CARDINAL HEALTH, INC.	-2.32%	23.98B
SINOPHARM GROUP CO. LTD.	+5.38%	8.8B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.52%	8.6B
HUADONG MEDICINE CO., LTD	-19.56%	8.07B
H. LUNDBECK A/S	+14.16%	5.26B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.13%	4.14B
GALENICA AG	-2.54%	3.88B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+24.77%	3.72B

Pharmaceuticals Wholesale

EBOS Group Limited

Equities

EBO

NZEBOE0001S6

Pharmaceuticals

EBOS Group Ltd. Reaffirms Earnings Guidance for the Six Months Ending December 31, 2013

Latest news about EBOS Group Limited

Chart EBOS Group Limited

Company Profile

Income Statement Evolution

Ratings for EBOS Group Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Pharmaceuticals Wholesale